The P2RY12 receptor promotes VSMC-derived foam cell formation by inhibiting autophagy in advanced atherosclerosis
Vascular smooth muscle cells (VSMCs) are an important source of foam cells in atherosclerosis. The mechanism for VSMC-derived foam cell formation is, however, poorly understood. Here, we demonstrate that the P2RY12/P2Y12 receptor is important in regulating macroautophagy/autophagy and VSMC-derived f...
Saved in:
| Published in | Autophagy Vol. 17; no. 4; pp. 980 - 1000 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Taylor & Francis
03.04.2021
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1554-8627 1554-8635 1554-8635 |
| DOI | 10.1080/15548627.2020.1741202 |
Cover
| Abstract | Vascular smooth muscle cells (VSMCs) are an important source of foam cells in atherosclerosis. The mechanism for VSMC-derived foam cell formation is, however, poorly understood. Here, we demonstrate that the P2RY12/P2Y12 receptor is important in regulating macroautophagy/autophagy and VSMC-derived foam cell formation in advanced atherosclerosis. Inhibition of the P2RY12 receptor ameliorated lipid accumulation and VSMC-derived foam cell formation in high-fat diet-fed apoe
-/-
mice (atherosclerosis model) independent of LDL-c levels. Activation of the P2RY12 receptor blocked cholesterol efflux via PI3K-AKT, while genetic knockdown or pharmacological inhibition of the P2RY12 receptor inhibited this effect in VSMCs. Phosphoproteomic analysis showed that the P2RY12 receptor regulated the autophagy pathway in VSMCs. Additionally, activation of the P2RY12 receptor inhibited MAP1LC3/LC3 maturation, SQSTM1 degradation, and autophagosome formation in VSMCs. Genetic knockdown of the essential autophagy gene Atg5 significantly attenuated P2RY12 receptor inhibitor-induced cholesterol efflux in VSMCs. Furthermore, activation of the P2RY12 receptor led to the activation of MTOR through PI3K-AKT in VSMCs, whereas blocking MTOR activity (rapamycin) or reducing MTOR expression reversed the inhibition of cholesterol efflux mediated by the P2RY12 receptor in VSMCs. In vivo, inhibition of the P2RY12 receptor promoted autophagy of VSMCs through PI3K-AKT-MTOR in advanced atherosclerosis in apoe
-/-
mice, which could be impeded by an autophagy inhibitor (chloroquine). Therefore, we conclude that activation of the P2RY12 receptor decreases cholesterol efflux and promotes VSMC-derived foam cell formation by blocking autophagy in advanced atherosclerosis. Our study thus suggests that the P2RY12 receptor is a therapeutic target for treating atherosclerosis.
Abbreviations: 2-MeSAMP: 2-methylthioadenosine 5′-monophosphate; 8-CPT-cAMP: 8-(4-chlorophenylthio)-adenosine-3ʹ,5ʹ-cyclic-monophosphate; ABCA1: ATP binding cassette subfamily A member 1; ABCG1: ATP binding cassette subfamily G member 1; ACTB: actin beta; ADPβs: adenosine 5′-(alpha, beta-methylene) diphosphate; ALs: autolysosomes; AMPK: AMP-activated protein kinase; APOA1: apolipoprotein A1; APs: autophagosomes; ATG5: autophagy related 5; ATV: atorvastatin; AVs: autophagic vacuoles; CD: chow diet; CDL: clopidogrel; CQ: chloroquine; DAPI: 4ʹ,6-diamidino-2-phenylindole; dbcAMP: dibutyryl-cAMP; DIL-oxLDL: dioctadecyl-3,3,3,3-tetramethylin docarbocyanine-oxLDL; EIF4EBP1/4E-BP1: eukaryotic translation initiation factor 4E binding protein 1; EVG: elastic van gieson; HE: hematoxylin-eosin; HDL: high-density lipoprotein; HFD: high-fat diet; KEGG: Kyoto Encyclopedia of Genes and Genomes; LDL-c: low-density lipoprotein cholesterol; LDs: lipid droplets; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; Masson: masson trichrome; MCPT: maximal carotid plaque thickness; MK2206: MK-2206 2HCL; NBD-cholesterol: 22-(N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl] amino)-23,24-bisnor-5-cholen-3β-ol; OLR1/LOX-1: oxidized low density lipoprotein receptor 1; ORO: oil Red O; ox-LDL: oxidized low-density lipoprotein; SQSTM1/p62: sequestosome 1; TEM: transmission electron microscopy; TIC: ticagrelor; ULK1: unc-51 like autophagy activating kinase 1; VSMCs: vascular smooth muscle cells |
|---|---|
| AbstractList | Vascular smooth muscle cells (VSMCs) are an important source of foam cells in atherosclerosis. The mechanism for VSMC-derived foam cell formation is, however, poorly understood. Here, we demonstrate that the P2RY12/P2Y12 receptor is important in regulating macroautophagy/autophagy and VSMC-derived foam cell formation in advanced atherosclerosis. Inhibition of the P2RY12 receptor ameliorated lipid accumulation and VSMC-derived foam cell formation in high-fat diet-fed apoe-/- mice (atherosclerosis model) independent of LDL-c levels. Activation of the P2RY12 receptor blocked cholesterol efflux via PI3K-AKT, while genetic knockdown or pharmacological inhibition of the P2RY12 receptor inhibited this effect in VSMCs. Phosphoproteomic analysis showed that the P2RY12 receptor regulated the autophagy pathway in VSMCs. Additionally, activation of the P2RY12 receptor inhibited MAP1LC3/LC3 maturation, SQSTM1 degradation, and autophagosome formation in VSMCs. Genetic knockdown of the essential autophagy gene Atg5 significantly attenuated P2RY12 receptor inhibitor-induced cholesterol efflux in VSMCs. Furthermore, activation of the P2RY12 receptor led to the activation of MTOR through PI3K-AKT in VSMCs, whereas blocking MTOR activity (rapamycin) or reducing MTOR expression reversed the inhibition of cholesterol efflux mediated by the P2RY12 receptor in VSMCs. In vivo, inhibition of the P2RY12 receptor promoted autophagy of VSMCs through PI3K-AKT-MTOR in advanced atherosclerosis in apoe-/- mice, which could be impeded by an autophagy inhibitor (chloroquine). Therefore, we conclude that activation of the P2RY12 receptor decreases cholesterol efflux and promotes VSMC-derived foam cell formation by blocking autophagy in advanced atherosclerosis. Our study thus suggests that the P2RY12 receptor is a therapeutic target for treating atherosclerosis. Abbreviations: 2-MeSAMP: 2-methylthioadenosine 5′-monophosphate; 8-CPT-cAMP: 8-(4-chlorophenylthio)-adenosine-3ʹ,5ʹ-cyclic-monophosphate; ABCA1: ATP binding cassette subfamily A member 1; ABCG1: ATP binding cassette subfamily G member 1; ACTB: actin beta; ADPβs: adenosine 5′-(alpha, beta-methylene) diphosphate; ALs: autolysosomes; AMPK: AMP-activated protein kinase; APOA1: apolipoprotein A1; APs: autophagosomes; ATG5: autophagy related 5; ATV: atorvastatin; AVs: autophagic vacuoles; CD: chow diet; CDL: clopidogrel; CQ: chloroquine; DAPI: 4ʹ,6-diamidino-2-phenylindole; dbcAMP: dibutyryl-cAMP; DIL-oxLDL: dioctadecyl-3,3,3,3-tetramethylin docarbocyanine-oxLDL; EIF4EBP1/4E-BP1: eukaryotic translation initiation factor 4E binding protein 1; EVG: elastic van gieson; HE: hematoxylin-eosin; HDL: high-density lipoprotein; HFD: high-fat diet; KEGG: Kyoto Encyclopedia of Genes and Genomes; LDL-c: low-density lipoprotein cholesterol; LDs: lipid droplets; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; Masson: masson trichrome; MCPT: maximal carotid plaque thickness; MK2206: MK-2206 2HCL; NBD-cholesterol: 22-(N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl] amino)-23,24-bisnor-5-cholen-3β-ol; OLR1/LOX-1: oxidized low density lipoprotein receptor 1; ORO: oil Red O; ox-LDL: oxidized low-density lipoprotein; SQSTM1/p62: sequestosome 1; TEM: transmission electron microscopy; TIC: ticagrelor; ULK1: unc-51 like autophagy activating kinase 1; VSMCs: vascular smooth muscle cells Vascular smooth muscle cells (VSMCs) are an important source of foam cells in atherosclerosis. The mechanism for VSMC-derived foam cell formation is, however, poorly understood. Here, we demonstrate that the P2RY12/P2Y12 receptor is important in regulating macroautophagy/autophagy and VSMC-derived foam cell formation in advanced atherosclerosis. Inhibition of the P2RY12 receptor ameliorated lipid accumulation and VSMC-derived foam cell formation in high-fat diet-fed mice (atherosclerosis model) independent of LDL-c levels. Activation of the P2RY12 receptor blocked cholesterol efflux via PI3K-AKT, while genetic knockdown or pharmacological inhibition of the P2RY12 receptor inhibited this effect in VSMCs. Phosphoproteomic analysis showed that the P2RY12 receptor regulated the autophagy pathway in VSMCs. Additionally, activation of the P2RY12 receptor inhibited MAP1LC3/LC3 maturation, SQSTM1 degradation, and autophagosome formation in VSMCs. Genetic knockdown of the essential autophagy gene significantly attenuated P2RY12 receptor inhibitor-induced cholesterol efflux in VSMCs. Furthermore, activation of the P2RY12 receptor led to the activation of MTOR through PI3K-AKT in VSMCs, whereas blocking MTOR activity (rapamycin) or reducing MTOR expression reversed the inhibition of cholesterol efflux mediated by the P2RY12 receptor in VSMCs. , inhibition of the P2RY12 receptor promoted autophagy of VSMCs through PI3K-AKT-MTOR in advanced atherosclerosis in mice, which could be impeded by an autophagy inhibitor (chloroquine). Therefore, we conclude that activation of the P2RY12 receptor decreases cholesterol efflux and promotes VSMC-derived foam cell formation by blocking autophagy in advanced atherosclerosis. Our study thus suggests that the P2RY12 receptor is a therapeutic target for treating atherosclerosis. 2-MeSAMP: 2-methylthioadenosine 5'-monophosphate; 8-CPT-cAMP: 8-(4-chlorophenylthio)-adenosine-3',5'-cyclic-monophosphate; ABCA1: ATP binding cassette subfamily A member 1; ABCG1: ATP binding cassette subfamily G member 1; ACTB: actin beta; ADPβs: adenosine 5'-(alpha, beta-methylene) diphosphate; ALs: autolysosomes; AMPK: AMP-activated protein kinase; APOA1: apolipoprotein A1; APs: autophagosomes; ATG5: autophagy related 5; ATV: atorvastatin; AVs: autophagic vacuoles; CD: chow diet; CDL: clopidogrel; CQ: chloroquine; DAPI: 4',6-diamidino-2-phenylindole; dbcAMP: dibutyryl-cAMP; DIL-oxLDL: dioctadecyl-3,3,3,3-tetramethylin docarbocyanine-oxLDL; EIF4EBP1/4E-BP1: eukaryotic translation initiation factor 4E binding protein 1; EVG: elastic van gieson; HE: hematoxylin-eosin; HDL: high-density lipoprotein; HFD: high-fat diet; KEGG: Kyoto Encyclopedia of Genes and Genomes; LDL-c: low-density lipoprotein cholesterol; LDs: lipid droplets; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; Masson: masson trichrome; MCPT: maximal carotid plaque thickness; MK2206: MK-2206 2HCL; NBD-cholesterol: 22-(N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl] amino)-23,24-bisnor-5-cholen-3β-ol; OLR1/LOX-1: oxidized low density lipoprotein receptor 1; ORO: oil Red O; ox-LDL: oxidized low-density lipoprotein; SQSTM1/p62: sequestosome 1; TEM: transmission electron microscopy; TIC: ticagrelor; ULK1: unc-51 like autophagy activating kinase 1; VSMCs: vascular smooth muscle cells. Vascular smooth muscle cells (VSMCs) are an important source of foam cells in atherosclerosis. The mechanism for VSMC-derived foam cell formation is, however, poorly understood. Here, we demonstrate that the P2RY12/P2Y12 receptor is important in regulating macroautophagy/autophagy and VSMC-derived foam cell formation in advanced atherosclerosis. Inhibition of the P2RY12 receptor ameliorated lipid accumulation and VSMC-derived foam cell formation in high-fat diet-fed apoe-/- mice (atherosclerosis model) independent of LDL-c levels. Activation of the P2RY12 receptor blocked cholesterol efflux via PI3K-AKT, while genetic knockdown or pharmacological inhibition of the P2RY12 receptor inhibited this effect in VSMCs. Phosphoproteomic analysis showed that the P2RY12 receptor regulated the autophagy pathway in VSMCs. Additionally, activation of the P2RY12 receptor inhibited MAP1LC3/LC3 maturation, SQSTM1 degradation, and autophagosome formation in VSMCs. Genetic knockdown of the essential autophagy gene Atg5 significantly attenuated P2RY12 receptor inhibitor-induced cholesterol efflux in VSMCs. Furthermore, activation of the P2RY12 receptor led to the activation of MTOR through PI3K-AKT in VSMCs, whereas blocking MTOR activity (rapamycin) or reducing MTOR expression reversed the inhibition of cholesterol efflux mediated by the P2RY12 receptor in VSMCs. In vivo, inhibition of the P2RY12 receptor promoted autophagy of VSMCs through PI3K-AKT-MTOR in advanced atherosclerosis in apoe-/- mice, which could be impeded by an autophagy inhibitor (chloroquine). Therefore, we conclude that activation of the P2RY12 receptor decreases cholesterol efflux and promotes VSMC-derived foam cell formation by blocking autophagy in advanced atherosclerosis. Our study thus suggests that the P2RY12 receptor is a therapeutic target for treating atherosclerosis.Abbreviations: 2-MeSAMP: 2-methylthioadenosine 5'-monophosphate; 8-CPT-cAMP: 8-(4-chlorophenylthio)-adenosine-3',5'-cyclic-monophosphate; ABCA1: ATP binding cassette subfamily A member 1; ABCG1: ATP binding cassette subfamily G member 1; ACTB: actin beta; ADPβs: adenosine 5'-(alpha, beta-methylene) diphosphate; ALs: autolysosomes; AMPK: AMP-activated protein kinase; APOA1: apolipoprotein A1; APs: autophagosomes; ATG5: autophagy related 5; ATV: atorvastatin; AVs: autophagic vacuoles; CD: chow diet; CDL: clopidogrel; CQ: chloroquine; DAPI: 4',6-diamidino-2-phenylindole; dbcAMP: dibutyryl-cAMP; DIL-oxLDL: dioctadecyl-3,3,3,3-tetramethylin docarbocyanine-oxLDL; EIF4EBP1/4E-BP1: eukaryotic translation initiation factor 4E binding protein 1; EVG: elastic van gieson; HE: hematoxylin-eosin; HDL: high-density lipoprotein; HFD: high-fat diet; KEGG: Kyoto Encyclopedia of Genes and Genomes; LDL-c: low-density lipoprotein cholesterol; LDs: lipid droplets; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; Masson: masson trichrome; MCPT: maximal carotid plaque thickness; MK2206: MK-2206 2HCL; NBD-cholesterol: 22-(N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl] amino)-23,24-bisnor-5-cholen-3β-ol; OLR1/LOX-1: oxidized low density lipoprotein receptor 1; ORO: oil Red O; ox-LDL: oxidized low-density lipoprotein; SQSTM1/p62: sequestosome 1; TEM: transmission electron microscopy; TIC: ticagrelor; ULK1: unc-51 like autophagy activating kinase 1; VSMCs: vascular smooth muscle cells.Vascular smooth muscle cells (VSMCs) are an important source of foam cells in atherosclerosis. The mechanism for VSMC-derived foam cell formation is, however, poorly understood. Here, we demonstrate that the P2RY12/P2Y12 receptor is important in regulating macroautophagy/autophagy and VSMC-derived foam cell formation in advanced atherosclerosis. Inhibition of the P2RY12 receptor ameliorated lipid accumulation and VSMC-derived foam cell formation in high-fat diet-fed apoe-/- mice (atherosclerosis model) independent of LDL-c levels. Activation of the P2RY12 receptor blocked cholesterol efflux via PI3K-AKT, while genetic knockdown or pharmacological inhibition of the P2RY12 receptor inhibited this effect in VSMCs. Phosphoproteomic analysis showed that the P2RY12 receptor regulated the autophagy pathway in VSMCs. Additionally, activation of the P2RY12 receptor inhibited MAP1LC3/LC3 maturation, SQSTM1 degradation, and autophagosome formation in VSMCs. Genetic knockdown of the essential autophagy gene Atg5 significantly attenuated P2RY12 receptor inhibitor-induced cholesterol efflux in VSMCs. Furthermore, activation of the P2RY12 receptor led to the activation of MTOR through PI3K-AKT in VSMCs, whereas blocking MTOR activity (rapamycin) or reducing MTOR expression reversed the inhibition of cholesterol efflux mediated by the P2RY12 receptor in VSMCs. In vivo, inhibition of the P2RY12 receptor promoted autophagy of VSMCs through PI3K-AKT-MTOR in advanced atherosclerosis in apoe-/- mice, which could be impeded by an autophagy inhibitor (chloroquine). Therefore, we conclude that activation of the P2RY12 receptor decreases cholesterol efflux and promotes VSMC-derived foam cell formation by blocking autophagy in advanced atherosclerosis. Our study thus suggests that the P2RY12 receptor is a therapeutic target for treating atherosclerosis.Abbreviations: 2-MeSAMP: 2-methylthioadenosine 5'-monophosphate; 8-CPT-cAMP: 8-(4-chlorophenylthio)-adenosine-3',5'-cyclic-monophosphate; ABCA1: ATP binding cassette subfamily A member 1; ABCG1: ATP binding cassette subfamily G member 1; ACTB: actin beta; ADPβs: adenosine 5'-(alpha, beta-methylene) diphosphate; ALs: autolysosomes; AMPK: AMP-activated protein kinase; APOA1: apolipoprotein A1; APs: autophagosomes; ATG5: autophagy related 5; ATV: atorvastatin; AVs: autophagic vacuoles; CD: chow diet; CDL: clopidogrel; CQ: chloroquine; DAPI: 4',6-diamidino-2-phenylindole; dbcAMP: dibutyryl-cAMP; DIL-oxLDL: dioctadecyl-3,3,3,3-tetramethylin docarbocyanine-oxLDL; EIF4EBP1/4E-BP1: eukaryotic translation initiation factor 4E binding protein 1; EVG: elastic van gieson; HE: hematoxylin-eosin; HDL: high-density lipoprotein; HFD: high-fat diet; KEGG: Kyoto Encyclopedia of Genes and Genomes; LDL-c: low-density lipoprotein cholesterol; LDs: lipid droplets; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; Masson: masson trichrome; MCPT: maximal carotid plaque thickness; MK2206: MK-2206 2HCL; NBD-cholesterol: 22-(N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl] amino)-23,24-bisnor-5-cholen-3β-ol; OLR1/LOX-1: oxidized low density lipoprotein receptor 1; ORO: oil Red O; ox-LDL: oxidized low-density lipoprotein; SQSTM1/p62: sequestosome 1; TEM: transmission electron microscopy; TIC: ticagrelor; ULK1: unc-51 like autophagy activating kinase 1; VSMCs: vascular smooth muscle cells. Vascular smooth muscle cells (VSMCs) are an important source of foam cells in atherosclerosis. The mechanism for VSMC-derived foam cell formation is, however, poorly understood. Here, we demonstrate that the P2RY12/P2Y12 receptor is important in regulating macroautophagy/autophagy and VSMC-derived foam cell formation in advanced atherosclerosis. Inhibition of the P2RY12 receptor ameliorated lipid accumulation and VSMC-derived foam cell formation in high-fat diet-fed apoe -/- mice (atherosclerosis model) independent of LDL-c levels. Activation of the P2RY12 receptor blocked cholesterol efflux via PI3K-AKT, while genetic knockdown or pharmacological inhibition of the P2RY12 receptor inhibited this effect in VSMCs. Phosphoproteomic analysis showed that the P2RY12 receptor regulated the autophagy pathway in VSMCs. Additionally, activation of the P2RY12 receptor inhibited MAP1LC3/LC3 maturation, SQSTM1 degradation, and autophagosome formation in VSMCs. Genetic knockdown of the essential autophagy gene Atg5 significantly attenuated P2RY12 receptor inhibitor-induced cholesterol efflux in VSMCs. Furthermore, activation of the P2RY12 receptor led to the activation of MTOR through PI3K-AKT in VSMCs, whereas blocking MTOR activity (rapamycin) or reducing MTOR expression reversed the inhibition of cholesterol efflux mediated by the P2RY12 receptor in VSMCs. In vivo, inhibition of the P2RY12 receptor promoted autophagy of VSMCs through PI3K-AKT-MTOR in advanced atherosclerosis in apoe -/- mice, which could be impeded by an autophagy inhibitor (chloroquine). Therefore, we conclude that activation of the P2RY12 receptor decreases cholesterol efflux and promotes VSMC-derived foam cell formation by blocking autophagy in advanced atherosclerosis. Our study thus suggests that the P2RY12 receptor is a therapeutic target for treating atherosclerosis. Abbreviations: 2-MeSAMP: 2-methylthioadenosine 5′-monophosphate; 8-CPT-cAMP: 8-(4-chlorophenylthio)-adenosine-3ʹ,5ʹ-cyclic-monophosphate; ABCA1: ATP binding cassette subfamily A member 1; ABCG1: ATP binding cassette subfamily G member 1; ACTB: actin beta; ADPβs: adenosine 5′-(alpha, beta-methylene) diphosphate; ALs: autolysosomes; AMPK: AMP-activated protein kinase; APOA1: apolipoprotein A1; APs: autophagosomes; ATG5: autophagy related 5; ATV: atorvastatin; AVs: autophagic vacuoles; CD: chow diet; CDL: clopidogrel; CQ: chloroquine; DAPI: 4ʹ,6-diamidino-2-phenylindole; dbcAMP: dibutyryl-cAMP; DIL-oxLDL: dioctadecyl-3,3,3,3-tetramethylin docarbocyanine-oxLDL; EIF4EBP1/4E-BP1: eukaryotic translation initiation factor 4E binding protein 1; EVG: elastic van gieson; HE: hematoxylin-eosin; HDL: high-density lipoprotein; HFD: high-fat diet; KEGG: Kyoto Encyclopedia of Genes and Genomes; LDL-c: low-density lipoprotein cholesterol; LDs: lipid droplets; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; Masson: masson trichrome; MCPT: maximal carotid plaque thickness; MK2206: MK-2206 2HCL; NBD-cholesterol: 22-(N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl] amino)-23,24-bisnor-5-cholen-3β-ol; OLR1/LOX-1: oxidized low density lipoprotein receptor 1; ORO: oil Red O; ox-LDL: oxidized low-density lipoprotein; SQSTM1/p62: sequestosome 1; TEM: transmission electron microscopy; TIC: ticagrelor; ULK1: unc-51 like autophagy activating kinase 1; VSMCs: vascular smooth muscle cells |
| Author | Liu, Jianyong Zhou, Lian Li, Yuanyuan He, Quanwei Miao, Yiliang Liu, Yuxiao Dang, Yiping Yu, Cheng Hu, Bo Shi, Hanqing Guo, Xiaoqing Jin, Huijuan Li, Yanan Mao, Ling Pi, Shulan Chen, Jiefang Yue, Zhenyu Xia, Yuanpeng He, Hui Hu, Yu |
| Author_xml | – sequence: 1 givenname: Shulan surname: Pi fullname: Pi, Shulan organization: Huazhong University of Science and Technology – sequence: 2 givenname: Ling surname: Mao fullname: Mao, Ling organization: Huazhong University of Science and Technology – sequence: 3 givenname: Jiefang surname: Chen fullname: Chen, Jiefang organization: Huazhong University of Science and Technology – sequence: 4 givenname: Hanqing surname: Shi fullname: Shi, Hanqing organization: Huazhong University of Science and Technology – sequence: 5 givenname: Yuxiao surname: Liu fullname: Liu, Yuxiao organization: Huazhong University of Science and Technology – sequence: 6 givenname: Xiaoqing surname: Guo fullname: Guo, Xiaoqing organization: Huazhong University of Science and Technology – sequence: 7 givenname: Yuanyuan surname: Li fullname: Li, Yuanyuan organization: Huazhong University of Science and Technology – sequence: 8 givenname: Lian surname: Zhou fullname: Zhou, Lian organization: Huazhong University of Science and Technology – sequence: 9 givenname: Hui surname: He fullname: He, Hui organization: Huazhong University of Science and Technology – sequence: 10 givenname: Cheng surname: Yu fullname: Yu, Cheng organization: Huazhong University of Science and Technology – sequence: 11 givenname: Jianyong surname: Liu fullname: Liu, Jianyong organization: Huazhong University of Science and Technology – sequence: 12 givenname: Yiping surname: Dang fullname: Dang, Yiping organization: Huazhong University of Science and Technology – sequence: 13 givenname: Yuanpeng surname: Xia fullname: Xia, Yuanpeng organization: Huazhong University of Science and Technology – sequence: 14 givenname: Quanwei surname: He fullname: He, Quanwei organization: Huazhong University of Science and Technology – sequence: 15 givenname: Huijuan surname: Jin fullname: Jin, Huijuan organization: Huazhong University of Science and Technology – sequence: 16 givenname: Yanan surname: Li fullname: Li, Yanan organization: Huazhong University of Science and Technology – sequence: 17 givenname: Yu surname: Hu fullname: Hu, Yu organization: Huazhong University of Science and Technology – sequence: 18 givenname: Yiliang surname: Miao fullname: Miao, Yiliang organization: Huazhong Agricultural University – sequence: 19 givenname: Zhenyu orcidid: 0000-0001-8730-8515 surname: Yue fullname: Yue, Zhenyu email: zhenyu.yue@mssm.edu organization: The Friedman Brain Institute, Icahn School of Medicine at Mount Sinai – sequence: 20 givenname: Bo surname: Hu fullname: Hu, Bo email: hubo@mail.hust.edu.cn organization: Huazhong University of Science and Technology |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32160082$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUV2L1DAUDbLifuhPUPLoS9d8tGmLIC6D7gorig6CTyFNb6aRNplNMiPz7013Zhb1QV-Sy7n3nMO95xydOO8AoeeUXFLSkFe0qspGsPqSEZahuqS5eITOZrxoBK9OHmpWn6LzGH8QwkXTsifolDMqCGnYGbpbDoA_sy_fKcMBNKyTD3gd_OQTRPzt68dF0UOwW-ix8WrCGsYxV2FSyXqHux22brCdTdatsNokvx7Uagax6rfK6cxTaYDgox7n18an6LFRY4Rnh_8CLd-_Wy5uittP1x8WV7eFrniZCsObthes7BhjptFVzaniIIwhXc0VBWj7vI0pSWUyzNveEM7qXtOKAzWCX6A3e9n1ppug1-BSUKNcBzupsJNeWflnx9lBrvxWNqRuhOBZ4OVBIPi7DcQkJxvn9ZUDv4mS8VrUnHDa5tEXv3s9mBzPnAde7wd0PkEMYKS26f6C2dqOkhI5hyqPoco5VHkINbOrv9hHg__x3u551t0n9tOHsZdJ7UYfTMjh2Cj5vyV-Ac-5ufI |
| CitedBy_id | crossref_primary_10_3390_app11199078 crossref_primary_10_1007_s10557_022_07414_z crossref_primary_10_3390_antiox10040516 crossref_primary_10_1002_tox_23961 crossref_primary_10_3389_fphys_2023_1118239 crossref_primary_10_5114_aoms_176676 crossref_primary_10_1002_advs_202409250 crossref_primary_10_1080_15384101_2024_2344943 crossref_primary_10_1186_s40001_023_01354_6 crossref_primary_10_3389_fphar_2022_997598 crossref_primary_10_1186_s12967_021_02727_3 crossref_primary_10_3389_fphar_2021_632378 crossref_primary_10_1016_j_phymed_2024_155939 crossref_primary_10_1038_s41401_021_00729_x crossref_primary_10_1142_S0192415X24500940 crossref_primary_10_1007_s00018_023_04786_9 crossref_primary_10_3390_cells10030625 crossref_primary_10_3389_fnins_2022_901688 crossref_primary_10_1016_j_bbi_2024_04_014 crossref_primary_10_3724_zdxbyxb_2023_0315 crossref_primary_10_3389_fcell_2024_1481505 crossref_primary_10_1016_j_jconrel_2023_12_047 crossref_primary_10_3389_fphar_2022_977870 crossref_primary_10_1186_s10020_022_00549_7 crossref_primary_10_1186_s10020_024_00901_z crossref_primary_10_1016_j_biopha_2024_117112 crossref_primary_10_1016_j_jare_2023_11_004 crossref_primary_10_1016_j_jep_2024_118125 crossref_primary_10_1155_2022_7479416 crossref_primary_10_31083_j_rcm2306206 crossref_primary_10_31083_j_rcm2309317 crossref_primary_10_3390_ijms24032600 crossref_primary_10_1002_adfm_202214655 crossref_primary_10_3390_ijms222212109 crossref_primary_10_3390_ijms242015418 crossref_primary_10_1073_pnas_2121133119 crossref_primary_10_1111_bph_15720 crossref_primary_10_3390_foods11213543 crossref_primary_10_1016_j_isci_2024_111009 crossref_primary_10_1016_j_jare_2024_08_030 crossref_primary_10_1016_j_trsl_2023_03_004 crossref_primary_10_1016_j_jare_2023_12_014 crossref_primary_10_3389_fphar_2024_1496639 crossref_primary_10_1016_j_yjmcc_2023_03_012 crossref_primary_10_1007_s11010_024_04984_4 crossref_primary_10_1016_j_matdes_2023_111807 crossref_primary_10_3390_ijms25147755 crossref_primary_10_1016_j_intimp_2023_110098 crossref_primary_10_1016_j_bbrc_2020_08_076 crossref_primary_10_1016_j_phymed_2024_155341 crossref_primary_10_58999_cijmr_v2i01_44 crossref_primary_10_1038_s41538_025_00371_5 crossref_primary_10_1016_j_envpol_2022_120437 crossref_primary_10_1038_s41419_023_06270_5 crossref_primary_10_3390_nu16213752 crossref_primary_10_3389_fcvm_2022_845942 crossref_primary_10_3389_fendo_2022_863708 crossref_primary_10_1161_ATVBAHA_123_319037 crossref_primary_10_1007_s10557_021_07229_4 crossref_primary_10_3389_fcvm_2022_918056 crossref_primary_10_3390_biom13010015 crossref_primary_10_2147_IJN_S474888 crossref_primary_10_1016_j_metabol_2022_155213 crossref_primary_10_3389_fcell_2021_809955 crossref_primary_10_1186_s12967_024_05966_2 crossref_primary_10_1093_burnst_tkad024 crossref_primary_10_1016_j_biopha_2022_113775 crossref_primary_10_1097_FJC_0000000000001446 crossref_primary_10_1016_j_bcp_2021_114689 crossref_primary_10_1002_mnfr_202200166 crossref_primary_10_1017_erm_2023_14 crossref_primary_10_1186_s40001_024_01739_1 crossref_primary_10_1186_s12872_023_03211_0 crossref_primary_10_1007_s13346_025_01792_1 crossref_primary_10_1002_mds_28197 crossref_primary_10_1016_j_talanta_2023_124772 crossref_primary_10_1155_2023_2677020 crossref_primary_10_3389_fimmu_2024_1368203 crossref_primary_10_1186_s13020_021_00431_4 crossref_primary_10_1538_expanim_21_0002 crossref_primary_10_2174_0929867331666230807154019 crossref_primary_10_1093_cvr_cvab158 crossref_primary_10_3390_cells14030183 crossref_primary_10_3389_fphar_2023_1232114 crossref_primary_10_18632_aging_205992 crossref_primary_10_1016_j_bbalip_2022_159276 crossref_primary_10_1007_s10787_023_01369_9 crossref_primary_10_1039_D4SC00761A crossref_primary_10_3390_biomedicines9091214 crossref_primary_10_1007_s00109_021_02109_8 crossref_primary_10_1007_s12265_021_10196_8 crossref_primary_10_3389_fphar_2025_1499418 crossref_primary_10_1016_j_phymed_2025_156488 crossref_primary_10_1016_j_bbadis_2024_167238 crossref_primary_10_1016_j_cca_2020_10_025 crossref_primary_10_1111_ene_16443 crossref_primary_10_1111_jcmm_18257 crossref_primary_10_1016_j_vph_2023_107146 crossref_primary_10_1002_ptr_8203 crossref_primary_10_1007_s10753_023_01926_y crossref_primary_10_1016_j_cellsig_2023_110732 crossref_primary_10_1016_j_jare_2024_12_019 crossref_primary_10_1161_ATVBAHA_120_314350 crossref_primary_10_1186_s12872_021_02146_8 crossref_primary_10_1007_s00395_022_00927_6 crossref_primary_10_1002_ddr_21937 crossref_primary_10_3389_fcvm_2024_1441123 crossref_primary_10_1021_acsptsci_3c00288 crossref_primary_10_3389_fimmu_2024_1490387 crossref_primary_10_1002_jcp_31363 crossref_primary_10_1016_j_fbio_2024_104773 crossref_primary_10_1007_s13105_021_00870_5 crossref_primary_10_1016_j_intimp_2024_113223 crossref_primary_10_1038_s41419_023_06054_x crossref_primary_10_1016_j_jpha_2024_101053 crossref_primary_10_1016_j_biopha_2022_113712 crossref_primary_10_1080_15384101_2020_1823731 crossref_primary_10_1080_0886022X_2023_2278314 crossref_primary_10_1007_s00018_023_04793_w crossref_primary_10_1111_1440_1681_13845 crossref_primary_10_3389_fmed_2024_1445550 crossref_primary_10_1186_s13054_025_05278_x |
| Cites_doi | 10.1016/j.atherosclerosis.2017.05.023 10.1007/978-1-59745-157-4_4 10.1038/nrm2245 10.4161/auto.3711 10.15252/emmm.201809736 10.1161/CIRCULATIONAHA.117.027462 10.1038/nm.3866 10.1016/j.freeradbiomed.2017.08.012 10.1016/j.cmet.2011.03.023 10.1016/j.cmet.2012.06.003 10.1016/j.ccell.2015.08.012 10.1161/01.STR.0000110221.54366.49 10.1016/j.cmet.2015.10.008 10.1161/CIRCRESAHA.108.182683 10.1038/s41591-019-0512-5 10.1038/s41569-019-0227-9 10.1161/ATVBAHA.110.213702 10.1038/ncb2152 10.1161/STROKEAHA.110.608539 10.1080/15548627.2017.1327942 10.1093/nar/gkm321 10.1161/CIRCRESAHA.108.188318 10.1038/cddis.2014.146 10.1161/ATVBAHA.115.306074 10.1038/ncomms14864 10.1161/CIRCRESAHA.115.307611 10.1161/CIRCRESAHA.116.309318 10.1016/j.ebiom.2018.12.023 10.1161/CIRCRESAHA.115.307182 10.1161/CIRCRESAHA.116.303804 10.1093/cvr/cvu028 10.1006/meth.2001.1262 10.1161/ATVBAHA.115.303395 10.1016/j.amjcard.2011.05.008 10.1016/S0140-6736(96)09457-3 10.1161/CIRCRESAHA.118.312782 10.1161/CIRCRESAHA.114.301174 10.1161/ATVBAHA.116.308725 10.1016/S0076-6879(08)04011-1 10.1093/cvr/cvy022 10.1016/j.jvs.2017.01.021 10.1080/15548627.2018.1505155 10.1007/s11302-012-9303-x 10.1016/j.atherosclerosis.2006.08.027 10.1212/01.wnl.0000303969.63165.34 10.1016/j.pharmthera.2018.02.002 10.1161/CIRCULATIONAHA.113.005015 10.1038/embor.2011.260 10.1038/nature07976 10.1016/S1474-4422(17)30038-8 10.1161/CIRCULATIONAHA.116.024503 10.3390/ijms18091865 10.1016/j.jacc.2007.03.025 10.1172/JCI66580 10.1080/15548627.2015.1100356 10.1080/15548627.2017.1319040 10.1007/s00018-018-2937-2 10.1161/ATVBAHA.111.240705 10.1007/s11239-006-9033-4 |
| ContentType | Journal Article |
| Copyright | 2020 Informa UK Limited, trading as Taylor & Francis Group 2020 2020 Informa UK Limited, trading as Taylor & Francis Group 2020 Informa UK Limited, trading as Taylor & Francis Group |
| Copyright_xml | – notice: 2020 Informa UK Limited, trading as Taylor & Francis Group 2020 – notice: 2020 Informa UK Limited, trading as Taylor & Francis Group 2020 Informa UK Limited, trading as Taylor & Francis Group |
| DBID | AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.1080/15548627.2020.1741202 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | S. PI ET AL |
| EISSN | 1554-8635 |
| EndPage | 1000 |
| ExternalDocumentID | PMC8078663 32160082 10_1080_15548627_2020_1741202 1741202 |
| Genre | Research Article Journal Article |
| GrantInformation_xml | – fundername: the National Natural Science Foundation of China grantid: 81974182 – fundername: the National Natural Science Foundation of China grantid: 81820108010 – fundername: the National Key Research and Development Program of China grantid: 2018YFC1312200 – fundername: the National Natural Science Foundation of China grantid: 81400969 – fundername: the National Natural Science Foundation of China grantid: 81771249 – fundername: the National Natural Science Foundation of China grantid: 81571139 – fundername: the Natural Science Foundation of Hubei Province of China grantid: 2016CFB518 – fundername: the National Natural Science Foundation of China grantid: 81601027 – fundername: the National Natural Science Foundation of China grantid: 81671147 |
| GroupedDBID | --- 0BK 0R~ 23N 30N 4.4 53G 5GY AAJMT AALDU AAMIU AAPUL AAQRR ABCCY ABFIM ABJNI ABLIJ ABPAQ ABPEM ABTAI ABXUL ABXYU ACGFS ACTIO ADBBV ADCVX ADGTB AEISY AENEX AEYOC AGDLA AHDZW AIJEM AKBVH AKOOK ALMA_UNASSIGNED_HOLDINGS ALQZU AOIJS AQRUH AVBZW AWYRJ BAWUL BLEHA CCCUG DGEBU DIK DKSSO E3Z EBS EMOBN F5P GTTXZ H13 HYE IPNFZ KYCEM LJTGL M4Z O9- OK1 P2P RIG RNANH ROSJB RPM RTWRZ SNACF TBQAZ TDBHL TEI TFL TFT TFW TQWBC TR2 TTHFI TUROJ ZGOLN AAGDL AAHIA AAYXX ADHGD AFRVT AIYEW CITATION TASJS AAGME ABFMO ACDHJ ACZPZ ADOPC ADYSH AURDB BFWEY C1A CWRZV EJD NPM PCLFJ 7X8 5PM |
| ID | FETCH-LOGICAL-c534t-f389d624b222f8c5731a3e6ff0b73a1ee9d368f405f3e639df0327dc153e1f63 |
| ISSN | 1554-8627 1554-8635 |
| IngestDate | Tue Sep 30 15:24:17 EDT 2025 Thu Sep 04 17:40:46 EDT 2025 Thu Apr 03 06:57:22 EDT 2025 Wed Oct 01 03:29:25 EDT 2025 Thu Apr 24 23:12:05 EDT 2025 Wed Dec 25 09:06:26 EST 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | foam cell P2RY12 receptor autophagy VSMC Atherosclerosis |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c534t-f389d624b222f8c5731a3e6ff0b73a1ee9d368f405f3e639df0327dc153e1f63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this article. |
| ORCID | 0000-0001-8730-8515 |
| OpenAccessLink | https://www.tandfonline.com/doi/pdf/10.1080/15548627.2020.1741202?needAccess=true |
| PMID | 32160082 |
| PQID | 2376730319 |
| PQPubID | 23479 |
| PageCount | 21 |
| ParticipantIDs | informaworld_taylorfrancis_310_1080_15548627_2020_1741202 proquest_miscellaneous_2376730319 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8078663 crossref_citationtrail_10_1080_15548627_2020_1741202 crossref_primary_10_1080_15548627_2020_1741202 pubmed_primary_32160082 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-04-03 |
| PublicationDateYYYYMMDD | 2021-04-03 |
| PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Autophagy |
| PublicationTitleAlternate | Autophagy |
| PublicationYear | 2021 |
| Publisher | Taylor & Francis |
| Publisher_xml | – name: Taylor & Francis |
| References | e_1_3_3_52_1 e_1_3_3_50_1 e_1_3_3_18_1 e_1_3_3_39_1 e_1_3_3_14_1 e_1_3_3_37_1 e_1_3_3_16_1 e_1_3_3_35_1 e_1_3_3_58_1 e_1_3_3_10_1 e_1_3_3_33_1 e_1_3_3_56_1 e_1_3_3_12_1 e_1_3_3_31_1 e_1_3_3_54_1 e_1_3_3_40_1 e_1_3_3_7_1 e_1_3_3_9_1 e_1_3_3_29_1 e_1_3_3_25_1 e_1_3_3_48_1 e_1_3_3_27_1 e_1_3_3_46_1 e_1_3_3_3_1 e_1_3_3_21_1 e_1_3_3_44_1 e_1_3_3_5_1 e_1_3_3_23_1 e_1_3_3_42_1 e_1_3_3_30_1 e_1_3_3_51_1 e_1_3_3_17_1 e_1_3_3_19_1 e_1_3_3_13_1 e_1_3_3_38_1 e_1_3_3_59_1 e_1_3_3_15_1 e_1_3_3_36_1 e_1_3_3_57_1 e_1_3_3_34_1 e_1_3_3_55_1 e_1_3_3_11_1 e_1_3_3_32_1 e_1_3_3_53_1 e_1_3_3_41_1 e_1_3_3_60_1 e_1_3_3_6_1 e_1_3_3_8_1 e_1_3_3_28_1 e_1_3_3_24_1 e_1_3_3_49_1 e_1_3_3_26_1 e_1_3_3_47_1 e_1_3_3_2_1 e_1_3_3_20_1 e_1_3_3_45_1 e_1_3_3_4_1 e_1_3_3_22_1 e_1_3_3_43_1 |
| References_xml | – ident: e_1_3_3_21_1 doi: 10.1016/j.atherosclerosis.2017.05.023 – ident: e_1_3_3_54_1 doi: 10.1007/978-1-59745-157-4_4 – ident: e_1_3_3_17_1 doi: 10.1038/nrm2245 – ident: e_1_3_3_30_1 doi: 10.4161/auto.3711 – ident: e_1_3_3_44_1 doi: 10.15252/emmm.201809736 – ident: e_1_3_3_48_1 doi: 10.1161/CIRCULATIONAHA.117.027462 – ident: e_1_3_3_23_1 doi: 10.1038/nm.3866 – ident: e_1_3_3_42_1 doi: 10.1016/j.freeradbiomed.2017.08.012 – ident: e_1_3_3_18_1 doi: 10.1016/j.cmet.2011.03.023 – ident: e_1_3_3_49_1 doi: 10.1016/j.cmet.2012.06.003 – ident: e_1_3_3_20_1 doi: 10.1016/j.ccell.2015.08.012 – ident: e_1_3_3_8_1 doi: 10.1161/01.STR.0000110221.54366.49 – ident: e_1_3_3_56_1 doi: 10.1016/j.cmet.2015.10.008 – ident: e_1_3_3_31_1 doi: 10.1161/CIRCRESAHA.108.182683 – ident: e_1_3_3_32_1 doi: 10.1038/s41591-019-0512-5 – ident: e_1_3_3_33_1 doi: 10.1038/s41569-019-0227-9 – ident: e_1_3_3_12_1 doi: 10.1161/ATVBAHA.110.213702 – ident: e_1_3_3_38_1 doi: 10.1038/ncb2152 – ident: e_1_3_3_40_1 doi: 10.1161/STROKEAHA.110.608539 – ident: e_1_3_3_47_1 doi: 10.1080/15548627.2017.1327942 – ident: e_1_3_3_60_1 doi: 10.1093/nar/gkm321 – ident: e_1_3_3_19_1 doi: 10.1161/CIRCRESAHA.108.188318 – ident: e_1_3_3_27_1 doi: 10.1038/cddis.2014.146 – ident: e_1_3_3_24_1 doi: 10.1161/ATVBAHA.115.306074 – ident: e_1_3_3_59_1 doi: 10.1038/ncomms14864 – ident: e_1_3_3_2_1 doi: 10.1161/CIRCRESAHA.115.307611 – ident: e_1_3_3_45_1 doi: 10.1161/CIRCRESAHA.116.309318 – ident: e_1_3_3_46_1 doi: 10.1016/j.ebiom.2018.12.023 – ident: e_1_3_3_15_1 doi: 10.1161/CIRCRESAHA.115.307182 – ident: e_1_3_3_37_1 doi: 10.1161/CIRCRESAHA.116.303804 – ident: e_1_3_3_10_1 doi: 10.1093/cvr/cvu028 – ident: e_1_3_3_58_1 doi: 10.1006/meth.2001.1262 – ident: e_1_3_3_5_1 doi: 10.1161/ATVBAHA.115.303395 – ident: e_1_3_3_11_1 doi: 10.1016/j.amjcard.2011.05.008 – ident: e_1_3_3_7_1 doi: 10.1016/S0140-6736(96)09457-3 – ident: e_1_3_3_3_1 doi: 10.1161/CIRCRESAHA.118.312782 – ident: e_1_3_3_36_1 doi: 10.1161/CIRCRESAHA.114.301174 – ident: e_1_3_3_13_1 doi: 10.1161/ATVBAHA.116.308725 – ident: e_1_3_3_55_1 doi: 10.1016/S0076-6879(08)04011-1 – ident: e_1_3_3_34_1 doi: 10.1093/cvr/cvy022 – ident: e_1_3_3_43_1 doi: 10.1016/j.jvs.2017.01.021 – ident: e_1_3_3_29_1 doi: 10.1080/15548627.2018.1505155 – ident: e_1_3_3_25_1 doi: 10.1007/s11302-012-9303-x – ident: e_1_3_3_22_1 doi: 10.1016/j.atherosclerosis.2006.08.027 – ident: e_1_3_3_39_1 doi: 10.1212/01.wnl.0000303969.63165.34 – ident: e_1_3_3_4_1 doi: 10.1016/j.pharmthera.2018.02.002 – ident: e_1_3_3_16_1 doi: 10.1161/CIRCULATIONAHA.113.005015 – ident: e_1_3_3_57_1 doi: 10.1038/embor.2011.260 – ident: e_1_3_3_28_1 doi: 10.1038/nature07976 – ident: e_1_3_3_6_1 doi: 10.1016/S1474-4422(17)30038-8 – ident: e_1_3_3_50_1 doi: 10.1161/CIRCULATIONAHA.116.024503 – ident: e_1_3_3_52_1 doi: 10.3390/ijms18091865 – ident: e_1_3_3_9_1 doi: 10.1016/j.jacc.2007.03.025 – ident: e_1_3_3_51_1 doi: 10.1172/JCI66580 – ident: e_1_3_3_53_1 doi: 10.1080/15548627.2015.1100356 – ident: e_1_3_3_41_1 doi: 10.1080/15548627.2017.1319040 – ident: e_1_3_3_26_1 doi: 10.1007/s00018-018-2937-2 – ident: e_1_3_3_35_1 doi: 10.1161/ATVBAHA.111.240705 – ident: e_1_3_3_14_1 doi: 10.1007/s11239-006-9033-4 |
| SSID | ssj0036892 |
| Score | 2.6387577 |
| Snippet | Vascular smooth muscle cells (VSMCs) are an important source of foam cells in atherosclerosis. The mechanism for VSMC-derived foam cell formation is, however,... |
| SourceID | pubmedcentral proquest pubmed crossref informaworld |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 980 |
| SubjectTerms | Atherosclerosis autophagy foam cell P2RY12 receptor Research Paper VSMC |
| Title | The P2RY12 receptor promotes VSMC-derived foam cell formation by inhibiting autophagy in advanced atherosclerosis |
| URI | https://www.tandfonline.com/doi/abs/10.1080/15548627.2020.1741202 https://www.ncbi.nlm.nih.gov/pubmed/32160082 https://www.proquest.com/docview/2376730319 https://pubmed.ncbi.nlm.nih.gov/PMC8078663 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1554-8635 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0036892 issn: 1554-8627 databaseCode: DIK dateStart: 20050101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVLSH databaseName: aylor and Francis Online customDbUrl: mediaType: online eissn: 1554-8635 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036892 issn: 1554-8627 databaseCode: AHDZW dateStart: 20050401 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1554-8635 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0036892 issn: 1554-8627 databaseCode: RPM dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVAWR databaseName: Taylor & Francis Science and Technology Library-DRAA customDbUrl: eissn: 1554-8635 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036892 issn: 1554-8627 databaseCode: 30N dateStart: 20050101 isFulltext: true titleUrlDefault: http://www.tandfonline.com/page/title-lists providerName: Taylor & Francis |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIiQuiDflJSNxq7LEdh7tcbUCrZCKEC1oOUV2YtNIS7JLU6TlZ_CLmYljJ60qluUSVdPYSTyf52GPZwh5LRQzPDYwvzmuVuUmDlQiZaAKliqmcAsR1yHnH5KTz9H70_h0NPo9iFraNOow_7X3XMn_cBVowFc8JXsNzvpOgQC_gb9wBQ7D9Z95_JF_-sr4BASXPgf_GQOuYPT1evJlMT8OCniNn2BTmlp-n-AifX9aEQ3PslqVqmwjn-UGUwxIew7QRwa09mG9hufCtVwPTdkj18BL1zYwYLHanPWIm8u68_y_9YEE3XmQUhvZkxcrWz9bVhfu5m4xgrM2hkUM5WccBeAkWR2qhzSblcQL3XQArmggQWe2sFOnjHH3Ya-gt5GR2DU-Dfx8HmJsFuMh7zWb283fUXg-DJF1-VFdNxl2k3Xd3CA3eZok3K0AWe0ukmlbaNt_qDsVNg3f7H2bLXtnKxvuPp9mNzR3YOss75I7nZNCjyzi7pGRru6TW7Zs6eUDcgG4oxZ31OGOOtzRIe4o4o4i7qjHHVWXtMcd9bgDInW4ozu4e0iW794uj0-CrnRHkMciagIDdnCR8EiB-WmmeZwKJoVOjAlVKiTTelbASBrwFgyQxawwoeBpkYP-1cwk4hE5qOpKPyE00VqBCax4KESkYqNYAVb6VKRMixCoYxK58c3yLq09Vlc5y_7K3TE59M3ObV6XqxrMhszLmnZBzdjqN5m4ou0rx-kMpDeOuqx0vVlnGJMGOhb04Jg8tpz3ryM4S9BCH5N0CxP-BswMv_1PVa7aDPFYRAJciafX_chn5HY_q5-Tg-bHRr8Ao7tRL9tZ8AcvE81y |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bT9swFD6amCZ4YYxx6cbFk_aaEtu50MepoiqMVoiVCZ6sOLFpBKRlTZHg13NOLlWLhnjgJQ9OTuI4x8efnc_fAfgpNbfCt9i_Ba1WxdZ3dBBFjk54qLmmX4i0DtnrB90L7-TSv5zbC0O0SppD21IooojV1LlpMbqmxB3QGIhIPMTpnXCJksMF6Ul-9ElphLZxuP06GsvgsEiMTCYO2dS7eF67zcL4tKBe-j8M-pJKOTc2dT5DXL9VSUm5aU5z3YyfXgg-vu-112C1gq7sV-lrX-CDydbhU5nM8vEr3KPHsTNxfsUFwzBqxjibZ-OC7Wcm7O-fXttJ0N0fTMLsKLpj9MuAzfZOMv3I0myY6pR42CyakuBBdE2FrOYpsAKtjib4dDymkw0YdI4G7a5TJXRwYl96uWMRHSWB8DSCEnsY-6HkkTSBta4OZcSNaSX4vSxiSIvFspVYV4owiTEqG24DuQlL2Sgz28ACYzQCIy1cKT3tW80TxG442eZGuljaAK_-iiquxM4p58at4pUmat2YihpTVY3ZgObMbFyqfbxl0Jp3EZUXyyy2zImi5Bu2P2p_UtinqdWjzIymE0VMJYy8GB0bsFX616w6UvCAcFsDwgXPm11AeuGLZ7J0WOiGU2oBBJjf3lHnfVjuDnqn6vS4__s7rAgi-BCNSe7AUv5vanYRoeV6r-iCz_uLLLk |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwEB1VrUBc2vK9tICRuGaJ7cTpHqvCqhS6qqAgOFlxbNOINrsl2Urtr2cmiVfdCtRDLzk4mcRxxuNn5_kNwFtpuBepx_4taLWq8GlkVJ5HxvLMcEO_EGkd8nCi9r8lBz_SwCase1olzaF9JxTRxmrq3DPrAyPuHQ2BCMQznN2JmBg5XJCc5Jqifaa0iyOehGAs1U6bF5lMIrIJm3j-d5ul4WlJvPRfEPQmk_La0DTeABNeqmOk_B7OGzMsrm7oPd7prTdhvQeubLfztIew4qpHcK9LZXn5GM7R39iR-PKTC4ZB1M1wLs9mLdfP1ez718O9yKKzXzjL_DQ_Y_TDgC12TjJzycrqpDQlsbBZPie5g_wXFbLAUmAtVp3W-HQ8lvUTOB5_ON7bj_p0DlGRyqSJPGIjq0RiEJL4nSLNJM-lU97HJpM5d25k8XN5RJAei-XI-liKzBYYkx33Sj6F1WpauefAlHMGYZERsZSJSb3hFpEbTrW5kzGWDiAJH1EXvdQ5Zdw41bxXRA2Nqakxdd-YAxguzGad1sdtBqPrHqKbdpHFdxlRtLzF9k1wJ409mlo9r9x0XmviKWHcxdg4gGedey2qIwVXhNoGkC053uICUgtfPlOVJ61qOCUWQHj54g51fg33j96P9eePk09b8EAQu4c4THIbVps_c_cS4VljXrUd8C878Stm |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+P2RY12+receptor+promotes+VSMC-derived+foam+cell+formation+by+inhibiting+autophagy+in+advanced+atherosclerosis&rft.jtitle=Autophagy&rft.au=Pi%2C+Shulan&rft.au=Mao%2C+Ling&rft.au=Chen%2C+Jiefang&rft.au=Shi%2C+Hanqing&rft.date=2021-04-03&rft.issn=1554-8627&rft.eissn=1554-8635&rft.volume=17&rft.issue=4&rft.spage=980&rft.epage=1000&rft_id=info:doi/10.1080%2F15548627.2020.1741202&rft.externalDBID=n%2Fa&rft.externalDocID=10_1080_15548627_2020_1741202 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1554-8627&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1554-8627&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1554-8627&client=summon |